John Bell & Croyden

CurrentBody Launches their Expert LED Devices in John Bell & Croyden

Retrieved on: 
Thursday, July 20, 2023
Technology, Luxury, Health Technology, Lifestyle, Health, Cosmetics, Consumer, Retail, Consumer Electronics, Harley Street, Pharmacy, Wigmore Street, LED, John Bell & Croyden, Beauty, John Bell, Entrepreneurship, Oil lamp, Hair loss, Skin

By bringing CurrentBody's expert LED devices to their esteemed clientele, they continue their commitment to offering cutting-edge solutions for beauty and wellbeing.

Key Points: 
  • By bringing CurrentBody's expert LED devices to their esteemed clientele, they continue their commitment to offering cutting-edge solutions for beauty and wellbeing.
  • CurrentBody's expert LED devices combine advanced technology with ease of use, enabling customers to enjoy professional-grade treatments in the comfort of their own homes.
  • “We are delighted to have CurrentBody's LED range in store at John Bell & Croyden,” General Manager, Alexander Johnston, shares.
  • It is a great honour to see our brand in the most famous pharmacy in the world.”
    Customers visiting John Bell & Croyden’s Wigmore Street store can now explore CurrentBody's range of expert LED devices, including: the highly acclaimed LED Light Therapy Face Mask and brand new LED Hair Regrowth Device.

DGAP-News: AURELIUS Equity Opportunities reports robust growth also in the first half of 2022 despite persistently tough economic conditions

Retrieved on: 
Thursday, August 11, 2022
John Bell & Croyden, Exercise, VAG, CEO, Container, Sport, ISIN, Sale, ESG, EBITDA, McKesson Corporation, Building material, Mission statement, NAV, Acquisition, An de Ryck, LloydsPharmacy, NDS, Final good, Saint-Gobain, JD Sports, RTS, Orica, Goal, BMC, AAH Pharmaceuticals, Minova, Industrial production, Security (finance), Renewable energy, Bank, Financial services, Retail, Group

The first half of 2022 was marked by extraordinary and persistent macroeconomic challenges.

Key Points: 
  • The first half of 2022 was marked by extraordinary and persistent macroeconomic challenges.
  • Despite persistent challenges in the market, AURELIUS Equity Opportunities sharpened the focus of its portfolio further in the first half of 2022.
  • The co-investment structure, operating jointly with AURELIUS European Opportunities Fund IV, made three new acquisitions in the first half of the year.
  • The AURELIUS Equity Opportunities Group expects a consistently constructive transaction environment in the second half of 2022.

Yooma Wellness Reports Results for Q4 and Fiscal 2021, Exceeding Forecasts with Revenue of US$5.3M in Q4 2021

Retrieved on: 
Tuesday, May 17, 2022
N8, QVC, Mission statement, Holland & Barrett, Rationalization, Today's Special, Stock, YOOM, Financial statement, EBay, John Bell & Croyden, LLC, LloydsPharmacy, Amazon (company), Marketing, CSE, Nihon TV Hai, Vertex, Rakuten, Casino, Administration, Acquisition, Growth, Skin care, GLOBE, Company, Vitality, Efficiency, Pharmacist, Royal warrant, Royal Warrant of Appointment (United Kingdom), Fuji TV, Canadian Securities Exchange, SEDAR, Special, Greenleaf, Oil, Industry, Sale, Carrefour, Yahoo!, Pharmacy, CEO, Security (finance), Reinsurance, Retail, Animal, Online shopping, Dietary supplement, Flour, USD, Amazon, Hemp, Selfridges, CBD, ASDA

Lorne Abony, Chairman at Yooma commented We are delighted with the Q4 results, which position Yooma as one of the largest publicly-listed CBD wellness companies outside of North America.

Key Points: 
  • Lorne Abony, Chairman at Yooma commented We are delighted with the Q4 results, which position Yooma as one of the largest publicly-listed CBD wellness companies outside of North America.
  • They also make it difficult to move to other regulated stock exchanges and raise the much-needed growth capital to support our brands.
  • The Company will make a further announcement in due course regarding the results of its strategic review.
  • Vitality CBD products continue to achieve premium rankings on Amazon UK for CBD search results and significant revenue growth.

DGAP-News: AURELIUS Equity Opportunities begins the 2022 financial year with a robust first quarter

Retrieved on: 
Thursday, May 12, 2022
ESG, History, Partners Group, EBITDA, VAG, ISIN, Share repurchase, BGP, Industrial production, AAH Pharmaceuticals, RTS, McKesson Corporation, Orica, NAV, Mining, CTD, Final good, Saint-Gobain, LloydsPharmacy, United Nations Global Compact, Sale, B2B, Container, BMC, Acquisition, John Bell & Croyden, Minova, CEO, Security (finance), Film, Financial services, Renewable energy, Risk management, EUR, Group

The first quarter of 2022 was characterized by a high level of transaction activity on the part of AURELIUS Equity Opportunities.

Key Points: 
  • The first quarter of 2022 was characterized by a high level of transaction activity on the part of AURELIUS Equity Opportunities.
  • Acting together with AURELIUS European Opportunities Fund IV, AURELIUS Equity Opportunities also expanded the jointly held portfolio through additional acquisitions.
  • Moreover, an additional analyst firm, Pareto Securities, has commenced coverage of AURELIUS Equity Opportunities with a buy recommendation.
  • AURELIUS Equity Opportunities will hold its 2022 annual general meeting on June 21, 2022.

DGAP-News: AURELIUS completes acquisition of LloydsPharmacy's parent company, McKesson UK

Retrieved on: 
Tuesday, April 12, 2022
Cardano, LloydsPharmacy, Aurelius Group, Life, Pharmacy, FRP, AEO, DLA, John Bell & Croyden, Rothschild, McKesson Corporation, Pension, Texas Homecare, Commercial, PricewaterhouseCoopers, Refugee, AAH Pharmaceuticals, Embassy of Luxembourg, London, Digital, Acquisition, Patient, Corporate finance, Commercial property, Security (finance), Financial services

AURELIUS completes acquisition of LloydsPharmacy's parent company, McKesson UK

Key Points: 
  • AURELIUS completes acquisition of LloydsPharmacy's parent company, McKesson UK
    The issuer is solely responsible for the content of this announcement.
  • AURELIUS completes acquisition of LloydsPharmacy's parent company, McKesson UK
    Luxembourg/London, April 07, 2022 - AURELIUS is pleased to announce that it has successfully closed the acquisition of McKesson UK.
  • McKesson UK is the parent company of a number of market leading healthcare businesses including LloydsPharmacy, John Bell & Croyden and AAH Pharmaceuticals.
  • AURELIUS will ensure a smooth transition as McKesson UK separates from its former US-based parent company, McKesson Corporation.

Yooma Wellness Reports Results for Third Quarter of 2021

Retrieved on: 
Monday, November 29, 2021
Nihon TV Hai, Financial statement, Company, EBay, Casino, EU, GLOBE, Marketing, American ginseng, Yahoo!, Skin care, Cannabinoid, CEO, Blood, Whole Foods Market, Royal warrant, John Bell & Croyden, HEB, Pharmacy, Melatonin, QVC, Sale, Oil, Royal Warrant of Appointment (United Kingdom), Vitality, Stock, SEDAR, Amazon (company), Acquisition, YOOM, Mission statement, CSE, Hemp, Pharmacist, Fuji TV, Rakuten, Selfridges, Ginkgo biloba, Video game, Dietary supplement, Online shopping, Retail, Airline

TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Yooma Wellness Inc. ("Yooma" or the "Company") (CSE: YOOM, AQSE:YOOM), a Toronto-based vertically-integrated global wellness platform that develops and markets a portfolio of wellness brands, today released its interim financial statements (the "Financial Statements") for the three-month period ended September 30, 2021 (the "Reporting Period").

Key Points: 
  • TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Yooma Wellness Inc. ("Yooma" or the "Company") (CSE: YOOM, AQSE:YOOM), a Toronto-based vertically-integrated global wellness platform that develops and markets a portfolio of wellness brands, today released its interim financial statements (the "Financial Statements") for the three-month period ended September 30, 2021 (the "Reporting Period").
  • Lorne Abony, Chairman at Yooma, commented: Yoomas success in the third quarter solidly-positions the Company in the global CBD and wellness space.
  • This dual-listing was successfully completed and the Companys common shares began trading on the AQSE on August 10, 2021.
  • Vitality CBD products continue to achieve premium rankings on Amazon UK for CBD search results, and significant quarter-over-quarter revenue growth.